It blocks pigment transfer to the keratinocyte and rebuilds ceramides. A 2015 trial also cut new skin cancers by 23% in high-risk patients — at 500 mg twice a day, oral.
Filed under CompoundConstellation SkinStatus Upcoming
Not yet investigated
What we have so far
It blocks pigment transfer to the keratinocyte and rebuilds ceramides. A 2015 trial also cut new skin cancers by 23% in high-risk patients — at 500 mg twice a day, oral.
This star is on the map because the show intends to take the question apart properly — the trials, how it is actually tested, whether the thing sold is the thing studied. That work is not done yet, and nothing here should be read as a conclusion. When the investigation is published it will appear on this page.
What we are reading
Gathered for the investigation and not yet written up. Each note says what the paper does and does not show.
Chen AC, Martin AJ, Choy B, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.N Engl J Med · 2015 · 373(17):1618-2610.1056/NEJMoa1506197 · PMID 26488693
ONTRAC. 386 high-risk participants, 500 mg twice daily for 12 months: new non-melanoma skin cancers 23% lower (95% CI 4 to 38, P=0.02). Note for the episode: the confidence interval reaches almost to 4%, the trial was in an Australian high-risk population, and the benefit VANISHED once the tablets stopped. Not a general-population claim.
